End-Stage Renal Disease Patients on Haemodialysis in Gezira State Central Sudan; Aetiology and Iron Status
Abstract
Background: This cross sectional study was conducted to determine the possible causes of chronic renal failure (CRF) and to monitor the iron status in order to reduce the mortality and morbidity in dialysis patients.
Resluts: Sixty eight CRF patients (36 men and 32 women) on regular haemodialysis were included in this study. Their mean age was 45.4 ± 17.8 years. Diabetes nephropathy (29%) was the commonest cause of CRF, followed by hypertension (21%), Glomerulonephritis (15%), Severe malaria (13%) and the least common one was polycystic kidney (3%). The mean serum iron was 57.7 ± 27.9 ng/ml, mean serum ferritin was 221.0 ± 170.1 ng/ml, and transferrin saturation (TSAT) was 22.8 ± 24.3%. Using TSAT, 15 (22.1%) patients had adequate (or normal) iron status (25.9 ± 4.4; 284.6 ± 111.0), 53 (77.9%) patients had iron deficiency (13.8 ± 2.6; 88.8 ± 37.7) and none had iron overload.
Conclusion: Our study suggests that, diabetes and hypertension are the conditions requiring strategies for prevention and treatment, and iron status of most cases is poor.
References
2- Hörl WH, Cavill I, MacDougall IC, Schaefer RM, Sunder-Plassmann G. How to diagnose and correct iron deficiency during r-HuEPO therapy: a consensus report. Nephrol Dial Transplant 1996; 11(2): 246-50.
3- Macdougall IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens. 1994; 3: 620-5.
4- Sesso R, Belasco AG. Late diagnosis of chronic renal failure and mortality on maintenance dialysis. Nephrol Dial Transplant. 1996; 11(12):2417-20.
5- Tuttle KR, Stein JH, DeFronzo RA. The natural history of diabetes nephropathy. Semin Nephrol 1990; 10(3): 184-93.
6- Rychlík I, Miltenberger-Miltenyi G, Ritz E. The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Nephrol Dial Transplant. 1998; 13 Suppl 8:6-10.
7- Mitwalli AH, Al-Swailem AR, Aziz KMS, Paul TT, Aswad S, Shaheen FAM, Alam AA. Etiology of end-stage renal disease in two regions of Saudi Arabia. Saudi J Kidney Dis Transplant 1997; 8(1): 16-20.
8- Chugh KS, Kumar R, Sakhuja V, Pereira BJ, Gupta A. Nephropathy in type 2 diabetes mellitus in Third World countries--Chandigarh study. Int J Artif Organs. 1989; 12(5):299-302.
9- Berglund J, Lins LE, Lins PE. Predictability in diabetic nephropathy. Acta Med Scand. 1984; 215(3):263-70.
10- Dasgupta I, Madeley RJ, Pringle MA, Savill J, Burden RP. Management of hypertension in patients developing end-stage renal failure. QJM. 1999; 92 (9):51925.
11- Brown TE, Carter BL. Hypertension and end-stage renal disease. Ann Pharmacother. 1994; 28(3):359-66.
12- Simon P, Ang KS, Cam G, Ramee MP. Epidemiology of chronic renal insufficiency treated by dialysis in a region in France. Changes in a 12- year period. Presse Med 1988; 17 (42): 2225-8.
13- Pasinski R, Pasinski M. End-stage renal disease among the Zuni Indians: 1973-1983. Arch Intern Med. 1987; 147(6):1093-6.
14- Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996; 334(1):13-8.
15- Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S120-41.
16- Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996; 49(5):1379-85.
17- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329(20):1456-62.
18- Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996; 334(15):939-45.
19- Schaefer RM, Schaefer L. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med. 1995; 23(1-2):83-8.
20- Braun J, Lindner K, Schreiber M, Heidler RA, Hörl WH. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant. 1997; 12(6):1173-81.
